Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR -Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Autor: Yang JC; National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan., Lee DH; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea., Lee JS; Seoul National University Bundang Hospital, Seoul, South Korea., Fan Y; Zhejiang Cancer Hospital, Hangzhou, China., de Marinis F; Istituto Europeo di Oncologia, IRCCS, Milan, Italy., Iwama E; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Inoue T; Osaka International Cancer Institute, Osaka, Japan., Rodríguez-Cid J; Oncology Center, Medica Sur Hospital, Mexico City, Mexico., Zhang L; Peking Union Medical College Hospital, Beijing, China., Yang CT; Chang Gung Memorial Hospital, Taoyuan, Taiwan., de la Mora Jimenez E; Instituto Jalisciense de Cancerología, Guadalajara, Mexico., Zhou J; The First Affiliated Hospital, Zhejiang University, Zhejiang, China., Pérol M; Centre Léon Bérard, Lyon, France., Lee KH; Chungbuk National University Hospital, Cheongju-si, South Korea., Vicente D; Hospital Universitario Virgen Macarena, Sevilla, Spain., Ichihara E; Okayama University Hospital, Okayama, Japan., Riely GJ; Memorial Sloan Kettering Cancer Center, New York, NY., Luo Y; Merck & Co, Inc, Rahway, NJ., Chirovsky D; Merck & Co, Inc, Rahway, NJ., Pietanza MC; Merck & Co, Inc, Rahway, NJ., Bhagwati N; Merck & Co, Inc, Rahway, NJ., Lu S; Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Dec; Vol. 42 (34), pp. 4029-4039. Date of Electronic Publication: 2024 Aug 22.

First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

Autor: Carbone, D., Ciuleanu, T., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., de La Mora Jimenez, E., Paz-Ares, L., Reck, M., John, T., Hu, N., Zhang, X., Tran, P., Grootendorst, D.J., Lu, S.

Publikováno v: Journal of Thoracic Oncology
Journal of Thoracic Oncology, 2021, 16 (10), pp.S862. ⟨10.1016/j.jtho.2021.08.061⟩

International audience

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1398::c91ee749a3e6848c0e1ef0107090826f
https://www.hal.inserm.fr/inserm-03540850

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Perioperative Oral Indomethacin Intake in Oncological Pancreatic Surgery as a Prevention of Surgical Complications

Autor: Santillan, V.M. Correa, Huezo, M.M. Ibarra, Novoa, M. Arias, De La Mora Jimenez, E., Limon, J.C. Vazquez

Publikováno v: In HPB 2023 25 Supplement 2:S497-S498

120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study

Autor: Yang, J.C-H., Luft, A., De La Mora Jiménez, E., Lee, J.S., Koralewski, P., Karadurmus, N., Sugawara, S., Livi, L., Basappa, N.S., Quantin, X., Dudnik, J., Moran Ortiz, D., Mekhail, T., Okpara, C.E., Zimmer, Z., Samkari, A., Bhagwati, N., Csőszi, T.

Publikováno v: In Annals of Oncology December 2021 32 Supplement 7:S1429-S1430